发明授权
- 专利标题： Bio-orthogonal drug activation
- 专利标题（中）： 生物正交药物活化
-
申请号： US14117246申请日： 2012-05-16
-
公开(公告)号： US09421274B2公开(公告)日： 2016-08-23
- 发明人: Marc Stefan Robillard , Hendricus Marie Janssen , Wolter Ten Hoeve , Ronny Mathieu Versteegen
- 申请人： Marc Stefan Robillard , Hendricus Marie Janssen , Wolter Ten Hoeve , Ronny Mathieu Versteegen
- 申请人地址： NL Eindhoven
- 专利权人： Koninklijke Philips N.V.
- 当前专利权人： Koninklijke Philips N.V.
- 当前专利权人地址： NL Eindhoven
- 优先权： EP11166241 20110516; EP11166942 20110520; EP11176736 20110805; EP11176741 20110805; EP11192572 20111208; EP11192577 20111208
- 国际申请： PCT/IB2012/052445 WO 20120516
- 国际公布： WO2012/156918 WO 20121122
- 主分类号： C07D257/08
- IPC分类号： C07D257/08 ; C07D237/26 ; C07C13/263 ; C07C33/16 ; A61K31/435 ; A61K31/502 ; A61K31/045 ; A61K47/48 ; B82Y5/00
摘要：
The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
公开/授权文献
- US20140199331A1 BIO-ORTHOGONAL DRUG ACTIVATION 公开/授权日：2014-07-17
信息查询
